Patients with childhood CML who are on imatinib (targets-c-kit, PDGFR-α/β, and VEGF) and are in remission have growth retardation by affecting GH/IGF-1 axis, probably acting on somatotrophs (5). Here, IGF1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.